Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

C Steenholdt; Y Palarasah; K Bendtzen; A Teisner; J Brynskov; Børge Teisner; C H Nielsen

doi:10.1111/apt.12330

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

C Steenholdt, Y Palarasah, K Bendtzen, A Teisner, J Brynskov, Børge Teisner, C H Nielsen

Mave-, Tarm- og Leversygdomme

44 Citationer (Scopus)

Abstract

Infliximab (IFX) is a chimeric murine/human anti-TNF antibody (Ab) used for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Loss of response is common and associated with development of anti-IFX Abs during ongoing therapy. However, human anti-murine immunoglobulin Abs are common and may cross-react with the murine part of IFX.

Originalsprog	Engelsk
Tidsskrift	Alimentary Pharmacology and Therapeutics
Vol/bind	37
Udgave nummer	12
Sider (fra-til)	1172-83
Antal sider	12
ISSN	0269-2813
DOI	https://doi.org/10.1111/apt.12330
Status	Udgivet - jun. 2013

Adgang til dokumentet

10.1111/apt.12330

Citationsformater

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. / Steenholdt, C; Palarasah, Y; Bendtzen, K et al.

I: Alimentary Pharmacology and Therapeutics, Bind 37, Nr. 12, 06.2013, s. 1172-83.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{21ac08944d3940d09b041a0ea536fde1,

title = "Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease",

abstract = "Infliximab (IFX) is a chimeric murine/human anti-TNF antibody (Ab) used for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Loss of response is common and associated with development of anti-IFX Abs during ongoing therapy. However, human anti-murine immunoglobulin Abs are common and may cross-react with the murine part of IFX.",

author = "C Steenholdt and Y Palarasah and K Bendtzen and A Teisner and J Brynskov and B{\o}rge Teisner and Nielsen, {C H}",

note = "{\textcopyright} 2013 John Wiley & Sons Ltd.",

year = "2013",

month = jun,

doi = "10.1111/apt.12330",

language = "English",

volume = "37",

pages = "1172--83",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "12",

}

TY - JOUR

T1 - Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

AU - Steenholdt, C

AU - Palarasah, Y

AU - Bendtzen, K

AU - Teisner, A

AU - Brynskov, J

AU - Teisner, Børge

AU - Nielsen, C H

PY - 2013/6

Y1 - 2013/6

N2 - Infliximab (IFX) is a chimeric murine/human anti-TNF antibody (Ab) used for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Loss of response is common and associated with development of anti-IFX Abs during ongoing therapy. However, human anti-murine immunoglobulin Abs are common and may cross-react with the murine part of IFX.

AB - Infliximab (IFX) is a chimeric murine/human anti-TNF antibody (Ab) used for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Loss of response is common and associated with development of anti-IFX Abs during ongoing therapy. However, human anti-murine immunoglobulin Abs are common and may cross-react with the murine part of IFX.

U2 - 10.1111/apt.12330

DO - 10.1111/apt.12330

M3 - Journal article

C2 - 23650912

VL - 37

SP - 1172

EP - 1183

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 12

ER -

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater